Breast Cancer Caregiver Survey: Women Being Treated with Herceptin-Perjeta Combination Therapy

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether the provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Herceptin-Perjeta combination therapy to treat HER2-positive early breast cancer. Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process. We would also like to speak with family